These results illustrated that the ODN1585 and anti-PD-1 antibody or anti-PD-L1 antibody combination indeed improved antitumor activity in the HCC mouse subcutaneous and orthotopic tumor model, which was consistent with animal research and clinical trial results 29, 30, 42. Here, CD274 is linked to neoplasm.